Predictive and progonstic biomarkers of nivolumab and pembrolizumab treatment in Renal cell and urothelial carcinoma
Latest Information Update: 05 Jun 2020
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Renal cell carcinoma; Urogenital cancer
- Focus Biomarker; Therapeutic Use
- Acronyms BINIR study
- 03 Jun 2020 Planned number of patients changed from 60 to 100.
- 18 May 2018 Planned number of patients changed from 50 to 60.
- 18 May 2018 Status changed from not yet recruiting to recruiting.